Psilocybin
Filament Health Announces Clinical Trial Approval in Partnership With Psychiatric Centre Copenhagen
Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical–stage natural psychedelic drug development company, today announced the approval…
Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical–stage natural psychedelic drug development company, today announced the approval of a clinical trial in partnership with Psychiatric Centre Copenhagen, Denmark’s largest psychiatric centre known for being at the forefront of new treatment options that stem from recognized research. The trial, led by PhD student Mathias Ebbesen Jensen and Professor Anders Fink-Jensen, will study Filament’s natural psilocybin drug candidate for the treatment of alcohol use disorder (AUD) and was recently approved by the Danish Medicines Agency.
Anders Fink-Jensen, Clinical Professor at Psychiatric Centre Copenhagen and the trial’s Principal Investigator“Alcohol use disorder is a widespread issue for global public health and constitutes a major risk factor for disability and mortality. Clinical data suggests that psilocybin holds potential for the treatment of AUD, and our intention with this trial is to expand on those findings.”
Five percent of all deaths worldwide each year result from the harmful use of alcohol. With this trial, Psychiatric Centre Copenhagen will determine the effects of a single administration of 25 milligrams of psilocybin on alcohol use and study the extent to which the brain is affected by psilocybin. Filament Health produces natural psilocybin, extracted from magic mushrooms. The GMP-released drug candidate has been exported from Filament’s Metro Vancouver lab and has arrived at the clinical site in Copenhagen in preparation for the trial’s start.
“Psychiatric Centre Copenhagen is an internationally recognized psychiatric research institution,” said Benjamin Lightburn, Chief Executive Officer and Co-Founder of Filament Health. “We are proud that Mathias Ebbesen Jensen and Professor Fink-Jensen have selected Filament’s drug candidate for a clinical trial of this calibre and we’re pleased to support their important research.”
This is the third European clinical trial which has been approved to use Filament’s natural psilocybin. The trial in Copenhagen will begin next month.
About Filament Health
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.
-
Psilocybin1 week ago
Are Shrooms Legal in Oregon: Full Guide
-
Psychedelics1 week ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Law & Regulation1 week ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psychedelics1 week ago
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics7 days ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics1 week ago
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Psilocybin3 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush